Management of glucocorticoid-induced osteoporosis: Prevalence, and emerging treatment options

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 49-59

  Payer, Juraj ^a   Brazdilova, Kristina ^a   Jackuliak, Peter ^a  

^a Physics and Informatics   (Slovakia)

Author keywords

Bisphosphonates; Bone mineral density; Calcium and vitamin D; Glucocorticoid induced osteoporosis; Osteoporotic fractures; Teriparatide

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANTIBIOTIC AGENT; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; MOUTHWASH; OSTEOCALCIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL WITHDRAWAL; BODY WEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEBRIDEMENT; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGITIS; ESOPHAGUS CANCER; EXERCISE; FALL RISK ASSESSMENT; FRACTURE; HUMAN; HYPERADRENOCORTICISM; HYPERCALCEMIA; HYPOGONADISM; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MOUTH HYGIENE; NONHUMAN; NUTRITIONAL HEALTH; OSTEOLYSIS; OSTEOSARCOMA; PATHOLOGIC FRACTURE; PATIENT COMPLIANCE; PATIENT MONITORING; PREVALENCE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; TREATMENT DURATION; TREATMENT PLANNING; VERTEBRA FRACTURE;

EID: 77955494858     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s7197     Document Type: Review

References (85)

1. Payer J, Killinger Z. Bone changes in hypercorticism. Rheumatol. 1999;13:181-183.
2. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-787.
3. Dale Carbonare L, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoidinduced and postmenopausal osteoporosis. J Bone Miner Res. 2001;16:97-103.
4. Van Staa TP, Leufkens HGM, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol. 2000;39:1383-1389.
5. Van Staa T, Leufkens HGM, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
6. De Gregório LH, Lacativa PG, Melazzi AC, et al. Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metabol. 2006;50:793-801.
7. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79:129-137.
8. Eastell R, Reid DM, Compston JE, Cooper C, et al. A UK consensus gruop on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998;244:271-292.
9. Hooyman JR, Melton LJ, Nelson AM, O'Fallon WM, Riggs BL. Fractures after rheumatoid arthritis a population based study. Arthritis Rheum. 1984;27:1353-1361.
10. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and the risk of hip fracture. Ann Rheum Dis. 1995;54:49-52.
11. Payer J, Rovenský J, Killinger Z. Lexicon of Osteoporosis. SAP; 2007:
12. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-397.
13. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
14. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of ostecytes on glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85:2907-2912.
15. Weinstein RS, Chen JR, Powers CC, Stewart SA, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041-1048.
16. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363-1374.
17. Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A, Nordin BEC. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int. 1990;46:305-308.
18. Sambrook P, Birmingham J, Kelly P, Kempler S, et al. Prevention of corticosteroid osteoporosis a comparison of calcium, calcitriol and calcitonin. N Engl J Med. 1993;328:1747-1752.
19. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab. 1998;83:801-806.
20. Alesci S, De Martino MU, Ilias I, et al. Glucocorticoid-Induced Osteoporosis: From Basic Mechanisms to Clinical Aspects. Neuroimmunomodulation. 2005;12:1-19.
21. Heffernan MP, Saag KG, Robinson JK, et al. Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA. 2006;295:1300.
22. Guidelines Writing Group for the Royal College for Physicians of London. Osteoporosis: Clinical Guidelines for Prevention and Teatment. London: Royal College for Physicians; 2002.
23. Aagaard EM, Lin P, Modin GW, et al. Prevention of glucocorticoidinduced osteoporosis: provider practice at an urban county hospital. Am J Med. 1999;107:456-460.
24. Lee YH, Lim YW, Ling PS, et al. Inadequate dietary calcium intake in elderly patients with hip fractures. Singapore Med J. 2007;48: 1117-1121.
25. Lems WF, Van Veen GJ, Gerrits MI, et al. Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br J Rheumatol. 1998;37:27-33.
26. Rovensky J, Payer J, editor. Bisphosphonates. Dictionary of Rheumatology. NewYork: SpringerWien; 2009. p. 24.
27. Mok CC, Tong KH, To CH, et al. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Ost Int. 2008;19: 357-364.
28. Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Ost Int. 2003;14:801-807.
29. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res. 2000;15: 1006-1013.
30. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001;69:242-247.
31. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone 1-34) with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:4528-4535.
32. Payer J, ierny D, Killinger Z, Šulková I, Behuliak M, Celec P. Preferences of patients with postmenopausal osteoporosis treated with bisphosphonates the VIVA II study. JIMR. 2009;37:1225-1229.
33. Payer J, Killinger Z, Šulková I, Celec P. Preferences of patients receiving bisphosphonates How to influence the therapeutic adherence. Biomed Pharmacother. 2008;62:122-124.
34. Rovensky J, Payer J editors. Osteonecrosis of the Jaw. Dictionary of Rheumatology. NewYork: SpringerWien; 2009. p. 158.
35. Miller PD. Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis: Bisphosphonate Safety. Osteoporosis. Elsevier; 2008:1733-1736.
36. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a registered-based national cohort study. J Bone Miner Res. 2009;24:1095-1102.
37. Singh AP. Oral bisphosphonates may cause esophageal cancer. N Engl J Med. 2009;1360:89-90.
38. Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol. 1997;36:255-259.
39. Cruse LM, Valeriano J, Vasey FB, et al. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol. 2006;12:221-225.
40. Yamada H. Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. Nippon Naibunpi Gakkai Zasshi. 1989;65:603-614.
41. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation. 1998;66:1004-1008.
42. Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, et al. Calcitonin, etidronate and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int. 1997;60:155-159.
43. Bianda T, Linka A, Junga G, Brunner H, et al. Prevention in osteoporosis in heart transplantation recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int. 2000;67:116-121.
44. Välimäki MJ, Kinnunen K, Tähtelä R, Loyttyniemi E, et al. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Osteoporos Int. 1999;10:128-136.
45. Cremer J, Struber M, Wagenbreth I, Mnischelsky J, et al. Progression of steroid-associated osteoporosis after heart transplantation. Ann Thoracic Surg. 1999;67:130-133.
46. Valero MA, Loinaz C, Larrodena L, Leon M, et al. Calcitonin and bisphosphonate treatment in bone loss after liver transplantation. Calcif Tissue Int. 1995;57:15-19.
47. Rizzato G, Tosi G, Schiraldi G, Montemurro L, Sisti DS. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis. 1988;5:99-103.
48. Luengo M, Pons F, Martinez de Osaba MJ, Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on longterm glucocorticoid therapy for asthma: a two year follow up study. Thorax. 1994;49:1099-1102.
49. Charlwood C, Manning EMC, Robinson J, Fraser WD. Comparison of pamidronate, calcitonin and cyclical etidronate in the treatment of osteoporosis associated with steroid therapy. J Bone Miner Res. 1997;12(Suppl 1):S510.
50. Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int. 1996;58:73-80.
51. Kotaniemi A, Piiraainen H, Paimela L, Leirisalo-Repo M, et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol. 1996;23:1875-1879.
52. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994;37:1499-1505.
53. Lane NE, Roe B, Genant HK, Arnaud C. Parathyroid hormone treatment reverses glucocorticoid-induced osteoporosis: results of a randomized controlled trial. J Clin Invest. 1998;102:1627-1633.
54. Drinkwater BL, Nilson K, Ott S, Chesnut CH. Bone mineral density after resumption of menses in amenorrheic women. JAMA. 1986;256: 380-382.
55. Drinkwater BL, Nilson K, Chesnut CH, Brenner WJ, Shainholtz S, Southworth WB. Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med. 1984;311:277-281.
56. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Huster WJ, Draper M, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1677.
57. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al; for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
58. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 1996;156:1173-1177.
59. Petak SM, Baskin HJ, Bergman DA, Dickey RA, Nankin HA. AACE clinical practice guidelines for the evaluation and treatment of hypogonadism in adult male patients. http://www.aace.com/clin/guides/ hypogonadism.html. Accessed December 20, 2000.
60. Jin L, Briggs SL, Chandrasekhar S, Chirgadze NY, Clawson D, et al. Crystal structure of human parathyroid hormone 1-34 at 0,9-A resolution. J Biol Chem. 2000;275:27238-27244.
61. ierny D, Killinger Z, Payer J. Place of teriparatide and intact parathormone in treatment of osteoporosis. Slov Lek. 2007;17:226-230.
62. Št pán J. Glucocorticoid-induced osteoporosis: New options of prevention and treatment. Interní Med. 2008;10:323-326.
63. Payer J, Killinger Z, Brázdilová K. Treatment algorithm of glucocorticoid induced osteoporosis. Vnit Lék. 2009;55:506-511.
64. Neer RM, Claude DA, Jose RZ, et al. Effect of Parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1431-1441.
65. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, See K, Dalsky GP, et al. Teriparatide versus Alendronate for Treatment of GlucocorticoidInduced Osteoporosis: 36-month Results. N Engl J Med. 2008; (Suppl 1):S49.
66. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
67. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165:1762-1768.
68. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 2007;22:149-157.
69. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strenght. Endocrinology. 2004;145:1835-1841.
70. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-211.
71. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res. 2003;18:919-924.
72. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277-285.
73. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
74. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292-299.
75. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, paralel-group study. Arthritis Rheum. 1999;42:2309-2318.
76. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355: 675-684.
77. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357: 2028-2039.
78. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for two years and relevance to human safety. Toxicol Pathol. 2002;30:312-321.
79. Betancourt M, Wirfel KL, Raymond AK, et al. Osteosarcoma of bone in a patient with primary hyperparathyroidism: a case report. J Bone Miner Res. 2003;18:163-166.
80. Adler RA, Curtis J, Weinstein RS, Saag KG. Management of Glucocorticoid-Induced Osteoporosis in Children.Elsevier; 2008:1156.
81. Kennel KA, Swiglo BA, Montori VM. Evidence-based osteoporosi care. In: Marcus R, Feldman D, Nelson DA, Rosen CJ, editors. Osteoporosis. Third Ed (Volume 2). Elsevier Academic Press; 2008. p. 1629-1650.
82. Recommendations for the Prevention and Treatment of GlucocorticoidInduced Osteoporosis. American College Of Rheumatology Ad Hoc Committee On Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44:1496-1503.
83. Saag KG. Prevention of glucocorticoid-induced osteoporosis. South Med J. 2004;97:555-558.
84. Geusens PP, de Nijs RNJ, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004;63:324-325.
85. Canalis E, Mazziotti G, Guitina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis Int. 2007;18: 1319-1328.